🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

18 recruiting trials

for Mucosal Melanoma

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma NCT04318717Phase 21 site📍 St Louis Washington University School of Medicine · Tests: Pembrolizumab, Hypofractionated radiation therapy Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) NCT05549297Phase 382 sites📍 Phoenix📍 Jacksonville📍 Orlando Immunocore Ltd · Tests: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial NCT07155317Phase 22 sites📍 Atlanta📍 Atlanta Emory University · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors NCT07600476Phase 13 sites📍 Munich📍 Würzburg📍 Münster Kupando GmbH · Tests: KUP-101A Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma NCT05546827Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Surgical resection Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) NCT06999980Phase 21 site📍 Wollstonecraft Melanoma Institute Australia · Tests: Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and rel… The Registry Study of Genetic Alterations of Melanoma in Taiwan NCT06952400n/a16 sites📍 Taipei📍 Chiayi City📍 Kaohsiung City National Health Research Institutes, Taiwan Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study NCT07215988n/a1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Non-Interventional Study Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma NCT07336979Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Paclitaxel Polymersomes Combined with Carboplatin and Adebelimab, Radical Surgery Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery NCT07400302Phase 21 site📍 Changchun The First Hospital of Jilin University · Tests: Sintilimab, Dacarbazine or Temozolomide, Cisplatin Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma NCT06319196Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Opdualag, Nivolumab Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan Axitinib and Nivolumab for the Treatment of Mucosal Melanoma NCT05384496Phase 22 sites📍 Harrison📍 New York Memorial Sloan Kettering Cancer Center · Tests: Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases NCT04511013Phase 2331 sites📍 Birmingham📍 Fairhope📍 Mobile SWOG Cancer Research Network · Tests: Binimetinib, Encorafenib, Ipilimumab, Nivolumab Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma NCT06961357Phase 1, Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Cyclophosphamide, Fludarabine, Interleukin-2, TIL Product SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126Phase 371 sites📍 Phoenix📍 Scottsdale📍 Duarte Immatics US, Inc. · Tests: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy NCT06797297Phase 231 sites📍 Hefei📍 Beijing📍 Beijing Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI363, Pembrolizumab Neo-adjuvant Immunotherapy in Patients With Localized Melanoma NCT07230613Phase 26 sites📍 Bordeaux📍 Lyon📍 Lyon UNICANCER · Tests: Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy